Prophylaxis of experimentally induced ovomucoid allergy in neonatal pigs using Lactococcus lactis.
Probiotic Lactococcus lactis (LL) is immunomodulatory and may prevent allergy by biasing from type-2 to a type-1 immune response. We hypothesized that newborn pigs pre-treated orally with LL are protected against allergy to ovomucoid (Ovm). Pigs were assigned to two treatment groups. Piglets were pretreated orally on days of age 1-7, 10, 12, 14, 21, 28 and 35 with LL (n=30) or medium (control, n=32) and sensitized to Ovm by intraperitoneal injection together with cholera toxin on days 14, 21 and 35. Pigs were orally challenged with egg white (day 46) and assigned scores for allergic signs. Outcomes were measured as direct skin tests, serum antibody to Ovm [IgG (H+L); IgE; IgG(1) and IgG(2)] and cytokine production by mitogen-stimulated blood mononuclear cells (BMC). Clinical signs and skin test positivity were less frequent in the LL group (p ≤ 0.0001). Serum antibody associated with IgG (H and L), IgE, IgG(1) or IgG(2) was significantly increased on day 46 (post-sensitization) compared to day 14 (pre-sensitization) (p ≤ 0.0001). The LL-treated pigs had more IgE and IgG(2)-related antibody activity and lower IgG(1)/IgG(2) and IgE/IgG(2) ratios indicating a type-1 bias in immune response (p ≤ 0.05). Concentration of type-2 cytokines interleukin IL-4 and IL-10 were significantly lower in supernatants of stimulated BMC of LL-treated pigs (p ≤ 0.0001). Interferon-γ, TGF-β and IL-13 were not detected in control or treated animals. Thus, oral treatment of neonatal pigs with LL significantly reduced subsequent frequency of allergy to Ovm associated with reduced type-2 immune response correlates hence supporting the "hygiene hypothesis" and potential use of LL as a neonatal immunoregulator.
Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada.
P
P
Rupa
J
J
Schmied
B N
BN
Wilkie
D000818:Animals; D000831:Animals, Newborn; D021181:Egg Hypersensitivity / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D018793:Interleukin-13 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D013294:Lactococcus lactis; D010059:Ovomucin / Q000009:adverse effects* / Q000276:immunology*; D019936:Probiotics / Q000627:therapeutic use*; D012882:Skin Tests / Q000662:veterinary; D034421:Sus scrofa; D016212:Transforming Growth Factor beta / Q000097:blood; D016896:Treatment Outcome
D007074:Immunoglobulin G; D018793:Interleukin-13; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D015847:Interleukin-4; D010059:Ovomucin; D007073:Immunoglobulin E; D007371:Interferon-gamma